// App-Quantinova.ai

EP327 : DASATINIB AND NAVITOCLAX REVERSE GLUCOCORTICOID RESISTANCE IN PRE-T-CELL RECEPTOR ACTIVATED T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA

Researchers

Presenter

  • Alistair Poll

Principal Investigators

  • Yuzhe Shi

  • Edward Law

  • Hayden Bell

  • Julie Irving

  • Frederik van Delft

Medical Centers

  • Centre for Cancer,Newcastle University,Newcastle upon Tyne,United Kingdom

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • T-cell acute lymphoblastic leukemia

  • Glucocorticoid resistance

Biomarkers

  • B-cell lymphoma 2

Drug/Treatment

  • Glucocorticoid

  • Navitoclax

  • Venetoclax

  • dasatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved